Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Casamayor is active.

Publication


Featured researches published by M. Casamayor.


Value in Health | 2015

A Systematic Literature Review of The Economic Implications of Acute Bacterial Skin And Skin Structure Infections (Absssis).

F. Degener; C Ivanescu; M. Casamayor; Maarten Postma

Objectives: During the years, acute bacterial skin and skin structure infections (ABSSSIs) have seen an increase in incidence in many parts of the western world. Additionally, the treatment of ABSSSIs, generally consisting of surgical debridement or drainage and empiric antibiotics in the hospital, can be further complicated by emerging multi drug resistant bacteria, most notably methicillin-resistant Staphylococcus aureus (MRSA). As the incidence rates increase alongside with rising antibiotic resistance, ABSSSIs are becoming a significant burden for healthcare systems. This study aims to collect evidence on the healthcare resource utilization of ABSSSI and the economic implications of different treatment modalities for the management of these diseases. Methods: A systematic literature search in MEDLINE, Cochane and ISPOR abstract databases with predefined inclusion criteria and subsequent quality assessment was performed. Results: The search identified 1,799 unique publications of which 26 contained relevant economic data on ABSSSIs treatment and were therefore included in this manuscript. There were six healthcare resource utilization studies, 11 cost analyses, three cost-minimization and six cost-effectiveness analyses, of which only a single study reported quality adjusted life years. Vancomycin was evaluated in most studies (21), followed by linezolid (15), daptomycin (8) and others (7). Conclusions: This review provides an in-depth overview of the economic implications of current ABSSSI management. Major cost drivers of ABSSSI treatment were length of hospital stay and the overall cost associated with frequent intravenous antibiotics administration. While most studies (20) applied a hospital perspective, there was a substantial disparity on the specific costs in- or excluded in the analysis, and on the unit prices. This led to significant variations of the final cost outcomes. Notably, over 10-fold differences were found. The overall quality and comparability of the literature reviewed was sub-optimal, elevating the need for more high-quality and reproducible economic evaluations in the area of ABSSSIs.


Value in Health | 2013

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also Known as Clostridium Difficile-Associated Diarrhoea (CDAD) in Spain

A. Van Engen; M. Casamayor; F. Loftus; E. Crimin; L. Lacey


Value in Health | 2017

The Global Burden Of Gastric (GC) And Gastroesophageal Junction (GEJC) Cancers

R Morlock; A Duran; S. Holmstrom; M. Casamayor; R Gani; Bj Pandya; A. Van Engen


Value in Health | 2016

Intravenous (IV) Admnistration of Morphine For Moderate-To-Severe Acute Pain In The Emergency Room (ER) Setting Inflicts A Substantial Economic Burden In The EU5

K DiDonato; Pp Palmer; Te Morris; J Walker; M. Casamayor; M Hennebert


Value in Health | 2015

Do Patient Reported Outcomes (Pro) In Oncology Matter In Health Technology Assessments (Hta)

M. Casamayor; D. Palazzolo; L Gubbels; P. Moïse; T Wijnands; M. Mantuano; C Ivanescu


Value in Health | 2014

‘De-Escalation’ Using Micafungin For The Treatment Of Systemic Candida Infection: Budget Impact In France And Germany

M. Casamayor; A. Van Engen; P. Musingarimi; Isaac Odeyemi; Olatunji Odufowora-Sita; M. Watt


Value in Health | 2014

Does Not Reaching an Agreement on the Final Nice Scope Have Any Impact on The Final Apraisal Outcome

M. Casamayor; L. Heemstra; Engen A. Van


Value in Health | 2014

Can A Global Value Dossier Meet Headquarters and Affiliates's Expectations?

Pj Kooreman; M. Casamayor; M. Schuchardt; Engen A. Van


Value in Health | 2013

Placebo-Controlled Trials: Are They Acceptable to Health Technology Assessment Bodies?

M. Casamayor; Cristina Ivanescu; A. Van Engen


Value in Health | 2012

PHP124 Comparison of HTA Dossier Requirements Across Europe

M. Casamayor; A. Van Engen

Collaboration


Dive into the M. Casamayor's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge